191 related articles for article (PubMed ID: 1970855)
1. [Efficacy and tolerability of 5-aminosalicylic acid in the short-term treatment of ulcerative rectocolitis during the mild or moderate stage].
Bresci G; Carrai M; Venturini G; Gambardella L
Minerva Dietol Gastroenterol; 1990; 36(1):31-3. PubMed ID: 1970855
[TBL] [Abstract][Full Text] [Related]
2. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
Kam L; Cohen H; Dooley C; Rubin P; Orchard J
Am J Gastroenterol; 1996 Jul; 91(7):1338-42. PubMed ID: 8677990
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity.
Bresci G; Carrai M; Venturini G; Gambardella L
Int J Tissue React; 1990; 12(4):243-6. PubMed ID: 1980911
[TBL] [Abstract][Full Text] [Related]
4. Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
Habal FM; Greenberg GR
Am J Gastroenterol; 1988 Jan; 83(1):15-9. PubMed ID: 2892391
[TBL] [Abstract][Full Text] [Related]
5. [Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
Jo Y; Matsumoto T; Iida M
Nihon Rinsho; 2005 May; 63(5):820-4. PubMed ID: 15881176
[TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Rutgeerts P
Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
[TBL] [Abstract][Full Text] [Related]
7. Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission.
Eliakim R; Wengrower D; Ligumsky M; Rachmilewitz D
Isr J Med Sci; 1990 Jan; 26(1):47-9. PubMed ID: 1968895
[No Abstract] [Full Text] [Related]
8. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Levine DS; Riff DS; Pruitt R; Wruble L; Koval G; Sales D; Bell JK; Johnson LK
Am J Gastroenterol; 2002 Jun; 97(6):1398-407. PubMed ID: 12094857
[TBL] [Abstract][Full Text] [Related]
9. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
Andreoli A; Spinella S; Levenstein S; Prantera C
Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
[TBL] [Abstract][Full Text] [Related]
10. [Drug therapy of ulcerative colitis].
Rückert Y
Z Arztl Fortbild Qualitatssich; 1997 Mar; 91(2):175-9. PubMed ID: 9244661
[TBL] [Abstract][Full Text] [Related]
11. 5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial.
Friedman LS; Richter JM; Kirkham SE; DeMonaco HJ; May RJ
Am J Gastroenterol; 1986 Jun; 81(6):412-8. PubMed ID: 3518408
[TBL] [Abstract][Full Text] [Related]
12. [New treatments of hemorrhagic rectocolitis].
Rambaud JC
Ann Gastroenterol Hepatol (Paris); 1988; 24(4):173-7. PubMed ID: 2901821
[TBL] [Abstract][Full Text] [Related]
13. Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Nakajima H; Munakata A; Yoshida Y
J Gastroenterol; 1995 Nov; 30 Suppl 8():115-7. PubMed ID: 8563870
[TBL] [Abstract][Full Text] [Related]
14. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Pruitt R; Hanson J; Safdi M; Wruble L; Hardi R; Johanson J; Koval G; Riff D; Winston B; Cross A; Doty P; Johnson LK
Am J Gastroenterol; 2002 Dec; 97(12):3078-86. PubMed ID: 12492193
[TBL] [Abstract][Full Text] [Related]
15. The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Baker DE; Kane S
Rev Gastroenterol Disord; 2004; 4(2):86-91. PubMed ID: 15185719
[TBL] [Abstract][Full Text] [Related]
16. [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
Schölmerich J; Gerok W
Wien Klin Wochenschr; 1986 Nov; 98(22):762-9. PubMed ID: 2880425
[TBL] [Abstract][Full Text] [Related]
17. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
18. Sulfasalazine and 5-ASA compounds.
Allgayer H
Gastroenterol Clin North Am; 1992 Sep; 21(3):643-58. PubMed ID: 1355468
[TBL] [Abstract][Full Text] [Related]
19. 5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.
Bondesen S; Nielsen OH; Jacobsen O; Rasmussen SN; Hansen SH; Halskov S; Binder V; Hvidberg EF
Scand J Gastroenterol; 1984 Jul; 19(5):677-82. PubMed ID: 6382570
[TBL] [Abstract][Full Text] [Related]
20. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
